Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …

Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a
decrease in viral load and the frequency of hospitalizations or emergency department visits …

Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

Given the evidence for a hyperactive platelet phenotype in COVID-19, we investigated
effector cell properties of COVID-19 platelets on endothelial cells (ECs). Integration of EC …

Background Little is known about the mortality of hospital-acquired (nosocomial) COVID-19
infection globally. We investigated the risk of mortality and critical care admission in …

B cell-targeting strategies such as rituximab are widely used in B cell hematologic
malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune …

Background Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
shedding has been described in immunocompromised coronavirus disease 2019 (COVID …

Importance Hospitalized patients with COVID-19 pneumonia have high rates of morbidity
and mortality. Objective To assess the efficacy of colchicine in hospitalized patients with …